우파다시티닙 시장 규모는 향후 수년간 급성장할 것으로 예측됩니다. 류마티스 관절염 발병률 증가, 환자 지원 프로그램 확대, 기존 DMARDs(질병 완화 항류마티스제)의 수용도 증가, 류마티스 관절염 증상에 대한 인식을 높이기 위한 정부의 대처, 치료에 대한 FDA 승인 증가 등입니다.
자가면역질환의 이환율 증가는 향후 몇 년간의 우파다시티닙 시장의 성장을 견인할 것으로 예측됩니다. 우파다시티닙은 JAK1을 선택적으로 억제함으로써 류마티스 관절염과 건선성 관절염과 같은 질병에서 염증을 억제하고 면역반응을 조절함으로써 자가면역질환 관리에 중요한 역할을 하고 있습니다. 예를 들어 2024년 11월 독일에 본사를 둔 의료 데이터 분석 기업인 Versorgungsatlas de는 2022년에 630만 4,340명이 적어도 하나의 자가면역질환으로 진단되었다고 보고하였으며, 이는 원시유병률 8.61%에 해당하는 수치입니다.
우파다시티닙 시장 진출기업은 자가면역질환을 관리하는 옵션을 늘리기 위해 경구 야누스키나아제(JAK) 억제제 등의 혁신적인 치료법의 개발을 우선하고 있습니다.
이러한 경구 억제제는 야누스 키나아제 효소를 저해하는 저분자제로 과도한 면역 활성과 염증을 억제하고, 자가면역 질환이나 염증성 질환을 효과적으로 치료합니다.
미국 기반의 제약 회사인 AbbVie Inc.는 RINVOQ(우파다시티닙)가 중등도에서 중증의 활동성 크론병 치료제로서 유럽위원회의 승인을 취득했다고 발표했습니다. 하루에 1회 투여가 가능해, 환자의 복약 준수와 치료의 편리성을 향상시킵니다. 전통의 치료제에 비해, 경구 투여는 작용 발현이 빠르기 때문에 환자는 치료 요법을 더 쉽게 유지하기 쉬워집니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 우파다시티닙 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 우파다시티닙 시장 : 성장률 분석
- 세계의 우파다시티닙 시장 실적 : 규모와 성장, 2019-2024
- 세계의 우파다시티닙 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계의 우파다시티닙 전체 시장 규모(TAM)
제6장 시장 세분화
- 세계의 우파다시티닙 시장 : 제품별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 야누스 키나아제 억제제
- 항류마티스약
- 저분자 의약품
- 세계의 우파다시티닙 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 류마티스 관절
- 건선성 관절염
- 크론병
- 세계의 우파다시티닙 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 홈케어
- 전문 클리닉
- 기타 최종 사용자
- 세계의 우파다시티닙 시장 : 야누스키나아제 억제제유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- JAK1 억제제
- JAK2 억제제
- JAK3 억제제
- TYK2 억제제
- 세계의 우파다시티닙 시장 : 항류마티스약유형별 하위 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 질환 수식 항류마티스약(DMARD)
- 생물학적 DMARD
- 종래의 합성 DMARD
- 세계의 우파다시티닙 시장 : 저분자 의약품유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 소분자 약
- 국소용 저분자약
제7장 지역별/국가별 분석
- 세계의 우파다시티닙 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 우파다시티닙 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 우파다시티닙 시장 : 경쟁 구도
- 우파다시티닙 시장 : 기업 프로파일
- Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
- Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- Curia Global Inc. Overview, Products and Services, Strategy and Financial Analysis
- Egis Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
- Natco Pharma
- Morepen Laboratories
- Zhejiang Hengkang Pharmaceutical
- Sinoway industrial Co. Ltd.
- Optimus Pharma
- Venkatasai Life Sciences
- Shandong Chenghui Shuangda Pharmaceutical Co. Ltd.
- Jinan Tantu Chemicals Co. Ltd.
- Shandong Loncom Pharmaceutical Co. Ltd.
- Lee Pharma
- TAPI Technology & API Services
- Hebi Xinhe Pharmaceutical
- Suzhou PengXu PharmaTech Co. Ltd.
- Anhui Dexinjia Biopharm Co. Ltd.
- Sichuan Qingmu Pharmaceutical Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 우파다시티닙 시장 2029 : 새로운 기회를 제공하는 국가
- 우파다시티닙 시장 2029 : 새로운 기회를 제공하는 부문
- 우파다시티닙 시장 2029 : 성장 전략
제36장 부록
SHW
Upadacitinib is a Janus kinase (JAK) inhibitor used to treat various inflammatory conditions by targeting and inhibiting specific enzymes involved in the inflammatory process. It is prescribed for moderate to severe rheumatoid arthritis (RA) and other autoimmune diseases, offering a targeted therapy alternative to traditional disease-modifying anti-rheumatic drugs (DMARDs) and biologics, with the added convenience of oral administration.
The primary product types of upadacitinib include Janus kinase inhibitors, antirheumatic agents, and small molecule drugs. Janus kinase (JAK) inhibitors work by blocking the activity of Janus kinase enzymes to reduce inflammation and manage autoimmune diseases. Upadacitinib is used for various applications, such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease, and is utilized by multiple end users, including hospitals, home care, specialty clinics, and others.
The upadacitinib market research report is one of a series of new reports from The Business Research Company that provides upadacitinib market statistics, including the upadacitinib industry global market size, regional shares, competitors with the upadacitinib market share, detailed upadacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the upadacitinib industry. This upadacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The upadacitinib market size has grown rapidly in recent years. It will grow from $1.32 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 14.8%. The growth during the historic period can be attributed to the rising incidence of autoimmune diseases, the expansion of patient assistance programs, an increase in positive regulatory approvals across various countries, higher disposable incomes, and improvements in healthcare infrastructure.
The upadacitinib market size is expected to see rapid growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The projected growth in the forecast period is driven by the increasing incidence of rheumatoid arthritis, the expansion of patient assistance programs, greater acceptance of traditional DMARDs, government initiatives to raise awareness of rheumatoid arthritis symptoms, and a rise in FDA approvals for treatment. Key trends include the adoption of targeted therapies and biomarkers, real-world data analysis, a stronger emphasis on value-based care, the development of specialized JAK inhibitors, and advancements in biologics.
The increasing incidence of autoimmune diseases is expected to drive the growth of the upadacitinib market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells, misidentifying them as foreign threats. The rising occurrence of these diseases is attributed to genetic predisposition, environmental triggers, and shifts in lifestyle and immune system function. Upadacitinib plays a crucial role in managing autoimmune conditions by selectively inhibiting JAK1, thereby reducing inflammation and modulating immune responses in disorders such as rheumatoid arthritis and psoriatic arthritis. For instance, in November 2024, Versorgungsatlas de, a Germany-based healthcare data analytics company, reported that 6,304,340 individuals were diagnosed with at least one autoimmune disease in 2022, corresponding to a raw prevalence rate of 8.61%. As a result, the increasing prevalence of autoimmune diseases is fueling the expansion of the upadacitinib market.
Companies operating in the upadacitinib market are prioritizing the development of innovative treatments, such as oral Janus kinase (JAK) inhibitors, to enhance options for managing autoimmune diseases. These oral inhibitors are small-molecule drugs that block Janus kinase enzymes, suppressing excessive immune activity and inflammation to effectively treat autoimmune and inflammatory conditions. For example, in April 2023, AbbVie Inc., a US-based pharmaceutical company, announced that RINVOQ (upadacitinib) had received European Commission approval for the treatment of moderately to severely active Crohn's disease. This oral formulation enables once-daily administration, improving patient adherence and treatment convenience. Compared to traditional therapies, the oral delivery method provides a faster onset of action, making it easier for patients to maintain their treatment regimens.
In November 2022, Caplin Point Laboratories Limited, an India-based pharmaceutical company, acquired an API plant from Metrochem API Private Limited for an undisclosed amount. This acquisition strengthens Caplin Point Laboratories' capacity to manufacture a wider range of high-quality API products, reinforcing its supply chain and expanding its reach in regulated markets. Metrochem API Private Limited, also based in India, is a pharmaceutical company involved in the production of upadacitinib.
Major players in the upadacitinib market are Merck & Co. Inc., AbbVie Inc, Eli Lilly and Company, Curia Global Inc., Egis Pharmaceuticals PLC, Natco Pharma, Morepen Laboratories, Zhejiang Hengkang Pharmaceutical, Sinoway industrial Co. Ltd., Optimus Pharma, Venkatasai Life Sciences, Shandong Chenghui Shuangda Pharmaceutical Co. Ltd., Jinan Tantu Chemicals Co. Ltd., Shandong Loncom Pharmaceutical Co. Ltd., Lee Pharma, TAPI Technology & API Services, Hebi Xinhe Pharmaceutical, Suzhou PengXu PharmaTech Co. Ltd., Anhui Dexinjia Biopharm Co. Ltd., Sichuan Qingmu Pharmaceutical Co. Ltd., Shandong Boyuan Pharmaceutical.
North America was the largest region in the upadacitinib market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in upadacitinib report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the upadacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The upadacitinib market consists of sales of immunosuppressants and anti-inflammatory agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Upadacitinib Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on upadacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for upadacitinib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The upadacitinib market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: Janus Kinase Inhibitors; Antirheumatic Agents; Small Molecule Drugs
- 2) By Application: Rheumatoid Arthritis; Psoriatic Arthritis; Crohn's Disease
- 3) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
- Subsegments:
- 1) By Janus Kinase Inhibitors: JAK1 Inhibitors; JAK2 Inhibitors; JAK3 Inhibitors; TYK2 Inhibitors
- 2) By Antirheumatic Agents: Disease-Modifying Antirheumatic Drugs (DMARDs); Biologic DMARDs; Conventional Synthetic DMARDs
- 3) By Small Molecule Drugs: Oral Small Molecule Drugs; Topical Small Molecule Drugs
- Companies Mentioned: Merck & Co. Inc.; AbbVie Inc; Eli Lilly and Company; Curia Global Inc.; Egis Pharmaceuticals PLC
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Upadacitinib Market Characteristics
3. Upadacitinib Market Trends And Strategies
4. Upadacitinib Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Upadacitinib Growth Analysis And Strategic Analysis Framework
- 5.1. Global Upadacitinib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Upadacitinib Market Growth Rate Analysis
- 5.4. Global Upadacitinib Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Upadacitinib Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Upadacitinib Total Addressable Market (TAM)
6. Upadacitinib Market Segmentation
- 6.1. Global Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Janus Kinase Inhibitors
- Antirheumatic Agents
- Small Molecule Drugs
- 6.2. Global Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Crohn's Disease
- 6.3. Global Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End-Users
- 6.4. Global Upadacitinib Market, Sub-Segmentation Of Janus Kinase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- JAK1 Inhibitors
- JAK2 Inhibitors
- JAK3 Inhibitors
- TYK2 Inhibitors
- 6.5. Global Upadacitinib Market, Sub-Segmentation Of Antirheumatic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Disease-Modifying Antirheumatic Drugs (DMARDs)
- Biologic DMARDs
- Conventional Synthetic DMARDs
- 6.6. Global Upadacitinib Market, Sub-Segmentation Of Small Molecule Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Small Molecule Drugs
- Topical Small Molecule Drugs
7. Upadacitinib Market Regional And Country Analysis
- 7.1. Global Upadacitinib Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Upadacitinib Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Upadacitinib Market
- 8.1. Asia-Pacific Upadacitinib Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Upadacitinib Market
- 9.1. China Upadacitinib Market Overview
- 9.2. China Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Upadacitinib Market
- 10.1. India Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Upadacitinib Market
- 11.1. Japan Upadacitinib Market Overview
- 11.2. Japan Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Upadacitinib Market
- 12.1. Australia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Upadacitinib Market
- 13.1. Indonesia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Upadacitinib Market
- 14.1. South Korea Upadacitinib Market Overview
- 14.2. South Korea Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Upadacitinib Market
- 15.1. Western Europe Upadacitinib Market Overview
- 15.2. Western Europe Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Upadacitinib Market
- 16.1. UK Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Upadacitinib Market
- 17.1. Germany Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Upadacitinib Market
- 18.1. France Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Upadacitinib Market
- 19.1. Italy Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Upadacitinib Market
- 20.1. Spain Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Upadacitinib Market
- 21.1. Eastern Europe Upadacitinib Market Overview
- 21.2. Eastern Europe Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Upadacitinib Market
- 22.1. Russia Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Upadacitinib Market
- 23.1. North America Upadacitinib Market Overview
- 23.2. North America Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Upadacitinib Market
- 24.1. USA Upadacitinib Market Overview
- 24.2. USA Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Upadacitinib Market
- 25.1. Canada Upadacitinib Market Overview
- 25.2. Canada Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Upadacitinib Market
- 26.1. South America Upadacitinib Market Overview
- 26.2. South America Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Upadacitinib Market
- 27.1. Brazil Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Upadacitinib Market
- 28.1. Middle East Upadacitinib Market Overview
- 28.2. Middle East Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Upadacitinib Market
- 29.1. Africa Upadacitinib Market Overview
- 29.2. Africa Upadacitinib Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Upadacitinib Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Upadacitinib Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Upadacitinib Market Competitive Landscape And Company Profiles
- 30.1. Upadacitinib Market Competitive Landscape
- 30.2. Upadacitinib Market Company Profiles
- 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Curia Global Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Egis Pharmaceuticals PLC Overview, Products and Services, Strategy and Financial Analysis
31. Upadacitinib Market Other Major And Innovative Companies
- 31.1. Natco Pharma
- 31.2. Morepen Laboratories
- 31.3. Zhejiang Hengkang Pharmaceutical
- 31.4. Sinoway industrial Co. Ltd.
- 31.5. Optimus Pharma
- 31.6. Venkatasai Life Sciences
- 31.7. Shandong Chenghui Shuangda Pharmaceutical Co. Ltd.
- 31.8. Jinan Tantu Chemicals Co. Ltd.
- 31.9. Shandong Loncom Pharmaceutical Co. Ltd.
- 31.10. Lee Pharma
- 31.11. TAPI Technology & API Services
- 31.12. Hebi Xinhe Pharmaceutical
- 31.13. Suzhou PengXu PharmaTech Co. Ltd.
- 31.14. Anhui Dexinjia Biopharm Co. Ltd.
- 31.15. Sichuan Qingmu Pharmaceutical Co. Ltd.
32. Global Upadacitinib Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Upadacitinib Market
34. Recent Developments In The Upadacitinib Market
35. Upadacitinib Market High Potential Countries, Segments and Strategies
- 35.1 Upadacitinib Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Upadacitinib Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Upadacitinib Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
